Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Change in Receivables (2023 - 2026)

Cannabis Bioscience International Holdings filings provide 4 years of Change in Receivables readings, the most recent being -$20545.0 for Q1 2026.

  • On a quarterly basis, Change in Receivables fell 83.78% to -$20545.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $21540.0, a 249.56% increase, with the full-year FY2025 number at $9155.0, down 10.14% from a year prior.
  • Change in Receivables reached -$20545.0 in Q1 2026 per CBIH's latest filing, down from $12845.0 in the prior quarter.
  • The five-year high for Change in Receivables was $26654.0 in Q2 2025, with the low at -$28765.0 in Q1 2023.
  • A 4-year average of -$651.62 and a median of -$1763.0 in 2024 define the central range for Change in Receivables.
  • Peak annual rise in Change in Receivables hit 760.64% in 2025, while the deepest fall reached 534.09% in 2025.
  • Year by year, Change in Receivables stood at -$8590.0 in 2023, then skyrocketed by 60.92% to -$3357.0 in 2024, then soared by 482.63% to $12845.0 in 2025, then tumbled by 259.95% to -$20545.0 in 2026.
  • Per Business Quant, the three most recent readings for CBIH's Change in Receivables are -$20545.0 (Q1 2026), $12845.0 (Q4 2025), and $2586.0 (Q3 2025).